Antimicrobial stewardship as part of the infection prevention effort

Current Infectious Disease Reports

Volumn 14, Issue 6, 2012, Pages 592-600

  Moehring, Rebekah W ^a,b   Anderson, Deverick J ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Antimicrobial pressure; Antimicrobial resistance; Antimicrobial stewardship; Antimicrobial utilization; Inappropriate antibiotic; Infection control; Infection prevention; Multidrug resistant; Preauthorization; Prospective audit and feedback

Indexed keywords

AZTREONAM; CARBAPENEM; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL STEWARDSHIP PROGRAM; ARTICLE; CLINICAL PROTOCOL; CLOSTRIDIUM DIFFICILE INFECTION; COMPUTERIZED PROVIDER ORDER ENTRY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; DIAGNOSTIC TEST; DISEASE ASSOCIATION; ENTEROBACTERIACEAE; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HEALTH PROGRAM; HOSPITAL COST; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PATIENT CARE; PATIENT SAFETY; PRESCRIPTION; PSEUDOMONAS; QUALITY ADJUSTED LIFE YEAR; TREATMENT DURATION;

EID: 84870514440     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0289-x     Document Type: Article

References (79)

1. World Health Organization. Global strategy for containment of antimicrobial resistance. http://www.who.int/drugresistance/WHO-Global-Strategy- English.pdf. Accessed 25 Aug 2012.
2. Centers for Disease Control and Prevention. Get smart: know when antibiotics work. http://www.cdc.gov/getsmart/. Accessed 25 Aug 2012.
3. Dellit TH, Owens RC, McGowan Jr JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44 (2):159-77.
4. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther. 2008;6(5):751-63.
5. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1-12.
6. Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med. 2003;163(8):972-8.
7. John Jr JF, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis. 1997;24(3):471-85.
8. Moody J, Cosgrove SE, Olmsted R, et al. Antimicrobial stewardship: a collaborative partnership between infection preventionists and healthcare epidemiologists. Infect Control Hosp Epidemiol. 2012;33(4):328-30.
9. Ohl CA, Dodds Ashley ES. Antimicrobial stewardship programs in community hospitals: the evidence base and case studies. Clin Infect Dis. 2011;53 Suppl 1:S23-S28.
10. McGowan JE. Antimicrobial stewardship -The state of the art in 2011: focus on outcome and methods. Infect Control Hosp Epidemiol. 2012;33(4):331-7. Excellent review of major research questions and existing literature in AS, along with a description of the limitations of existing research and directions for future study.
11. Ohl CA, Luther VP. Antimicrobial stewardship for inpatient facilities. J Hosp Med. 2011;6 Suppl 1:S4-S15.
12. Tamma PD, Cosgrove SE. Antimicrobial stewardship. Infect Dis Clin North Am. 2011;25(1):245-60.
13. Madaras-Kelly KJ, Remington RE, Lewis PG, Stevens DL. Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use. Infect Control Hosp Epidemiol. 2006;27(2):155-69.
14. Lewis GJ, Fang X, Gooch M, Cook PP. Decreased resistance of Pseudomonas aeruginosa with restriction of ciprofloxacin in a large teaching hospital's intensive care and intermediate care units. Infect Control Hosp Epidemiol. 2012;33(4):368-73.
15. Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2002;46(6):1619-28.
16. Calil R, Marba ST, von Nowakonski A, Tresoldi AT. Reduction in colonization and nosocomial infection by multiresistant bacteria in a neonatal unit after institution of educational measures and restriction in the use of cephalosporins. Am J Infect Control. 2001;29(3):133-8.
17. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993;119(5):353-8.
18. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 1998;280(14):1233-7.
19. Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet. 1994;344(8933):1329-32.
20. Rahal JJ, Urban C, Segal-Maurer S. Nosocomial antibiotic resistance in multiple gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clin Infect Dis. 2002;34(4):499-503.
21. Burke JP. Antibiotic resistance -squeezing the balloon? JAMA. 1998;280(14):1270-1.
22. Aldeyab MA, Devine MJ, Flanagan P, et al. Multihospital outbreak of Clostridium difficile ribotype 027 infection: epidemiology and analysis of control measures. Infect Control Hosp Epidemiol. 2011;32(3):210-9.
23. Valiquette L, Cossette B, Garant MP, Diab H, Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-Associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis. 2007;45 Suppl 2: S112-21.
24. TalpaertMJ, Gopal Rao G, Cooper BS,Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother. 2011;66(9):2168-74.
25. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7years. Infect Control Hosp Epidemiol. 2003;24(9):699-706.
26. Nathwani D, Sneddon J, Malcolm W, et al. Scottish Antimicrobial Prescribing Group (SAPG): development and impact of the Scottish National Antimicrobial Stewardship Programme. Int J Antimicrob Agents. 2011;38(1):16-26.
27. Elligsen M, Walker SA, Pinto R, et al. Audit and feedback to reduce broad-spectrum antibiotic use among intensive care unit patients: a controlled interrupted time series analysis. Infect Control Hosp Epidemiol. 2012;33(4):354-61.
28. Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N. Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother. 2011;66(6):1223-30.
29. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462-74.
30. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296-327.
31. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118(1):146-55.
32. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003;115(7):529-35.
33. Bauer KA, West JE, Balada-Llasat JM, Pancholi P, Stevenson KB, Goff DA. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis. 2010;51(9):1074-80.
34. Stevenson KB, Balada-Llasat JM, Bauer K, et al. The economics of antimicrobial stewardship: the current state of the art and applying the business case model. Infect Control Hosp Epidemiol. 2012;33(4):389-97.
35. Fishman N. Antimicrobial stewardship. Am J Med. 2006;119(6 Suppl 1):S53-61. discussion S64-S73.
36. Beardsley JR, Williamson JC, Johnson JW, Luther VP, Wrenn RH, Ohl CC. Show me the money: long-Term financial impact of an antimicrobial stewardship program. Infect Control Hosp Epidemiol. 2012;33(4):398-400.
37. Standiford HC, Chan S, Tripoli M, Weekes E, Forrest GN. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol. 2012;33(4):338-45.
38. Jacob JT, Gaynes RP. Emerging trends in antibiotic use in US hospitals: quality, quantification and stewardship. Expert Rev Anti Infect Ther. 2010;8(8):893-902.
39. Scheetz MH, Bolon MK, Postelnick M, Noskin GA, Lee TA. Costeffectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis. J Antimicrob Chemother. 2009;63(4):816-25.
40. McNulty CA, Lasseter GM, Charlett A, et al. Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections? J Antimicrob Chemother. 2011;66(6):1396-404.
41. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev 2005(4):CD003539.
42. Condon RE, Schulte WJ, Malangoni MA, Anderson-Teschendorf MJ. Effectiveness of a surgical wound surveillance program. Arch Surg. 1983;118(3):303-7.
43. Anderson DJ, Kaye KS, Classen D, et al. Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29 Suppl 1:S51-61.
44. Arnold FW, McDonald LC, Smith RS, Newman D, Ramirez JA. Improving antimicrobial use in the hospital setting by providing usage feedback to prescribing physicians. Infect Control Hosp Epidemiol. 2006;27(4):378-82.
45. Ibrahim OM, Polk RE. Benchmarking antimicrobial drug use in hospitals. Expert Rev Anti Infect Ther. 2012;10(4):445-57.
46. Linkin DR, Paris S, Fishman NO, Metlay JP, Lautenbach E. Inaccurate communications in telephone calls to an antimicrobial stewardship program. Infect Control Hosp Epidemiol. 2006;27 (7):688-94.
47. Linkin DR, Fishman NO, Landis JR, et al. Effect of communication errors during calls to an antimicrobial stewardship program. Infect Control Hosp Epidemiol. 2007;28(12):1374-81.
48. Buising KL, Thursky KA, Robertson MB, et al. Electronic antibiotic stewardship -reduced consumption of broad-spectrum antibiotics using a computerized antimicrobial approval system in a hospital setting. J Antimicrob Chemother. 2008;62(3):608-16.
49. Chan YY, Lin TY, Huang CT, et al. Implementation and outcomes of a hospital-wide computerised antimicrobial stewardship programme in a large medical centre in Taiwan. Int J Antimicrob Agents. 2011;38(6):486-92.
50. White Jr AC, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997;25(2):230-9.
51. Lautenbach E, LaRosa LA, Marr AM, Nachamkin I, Bilker WB, Fishman NO. Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and thirdgeneration cephalosporins. Clin Infect Dis. 2003;36(4):440-6.
52. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-Acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA. 2000;283(6):749-55.
53. Evans RS, Classen DC, Pestotnik SL, Lundsgaarde HP, Burke JP. Improving empiric antibiotic selection using computer decision support. Arch Intern Med. 1994;154(8):878-84.
54. Mullett CJ, Thomas JG, Smith CL, Sarwari AR, Khakoo RA. Computerized antimicrobial decision support: an offline evaluation of a database-driven empiric antimicrobial guidance program in hospitalized patients with a bloodstream infection. Int J Med Inform. 2004;73(5):455-60.
55. Evans RS, Pestotnik SL, Classen DC, et al. A computer-Assisted management program for antibiotics and other antiinfective agents. New Engl J Med. 1998;338(4):232-8.
56. Drew RH, Kawamoto K, Adams MB. Information technology for optimizing the management of infectious diseases. Am J Health Syst Pharm. 2006;63(10):957-65.
57. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-Assisted decision support: clinical and financial outcomes. Ann Intern Med. 1996;124(10):884-90.
58. Evans RS, Pestotnik SL, Classen DC, Burke JP. Evaluation of a computer-Assisted antibiotic-dose monitor. Ann Pharmacother. 1999;33(10):1026-31.
59. Paul M, Andreassen S, Tacconelli E, et al. Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. J Antimicrob Chemother. 2006;58(6):1238-45.
60. Briceland LL, Nightingale CH, Quintiliani R, Cooper BW, Smith KS. Antibiotic streamlining from combination therapy to monotherapy utilizing an interdisciplinary approach. Arch Intern Med. 1988;148(9):2019-22.
61. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-Associated pneumonia. Chest. 2004;125 (5):1791-9.
62. Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-Associated pneumonia and negative quantitative BAL culture results. Chest. 2005;128 (4):2706-13.
63. Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis. 2011;52 (10):1232-40. Review article in which the authors emphasize limited treatment duration as a target to reduce overallantimicrobial consumption. This articles provides a succinct summary with references to randomized trials that support recommendations of short duration, making it an easy-To-digest, evidencebased reference that is ideal for front-line AS education. The authors also provide an excellent summary of currently published data on use of the biomarker, procalcitonin.
64. Marra AR, de Almeida SM, Correa L, et al. The effect of limiting antimicrobial therapy duration on antimicrobial resistance in the critical care setting. Am J Infect Control. 2009;37(3):204-9.
65. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilatorassociated pneumonia. Crit Care Med. 2001;29(6):1109-15.
66. Kaye KS, Anderson DJ, Choi Y, Link K, Thacker P, Sexton DJ. The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clin Infect Dis. 2008;46 (10):1568-77.
67. Shiley KT, Lautenbach E, Lee I. The use of antimicrobial agents after diagnosis of viral respiratory tract infections in hospitalized adults: antibiotics or anxiolytics? Infect Control Hosp Epidemiol. 2010;31(11):1177-83.
68. Hermsen ED, VanSchooneveld TC, Sayles H, Rupp ME. Implementation of a clinical decision support system for antimicrobial stewardship. Infect Control Hosp Epidemiol. 2012;33(4):412-5.
69. McGregor JC, Weekes E, Forrest GN, et al. Impact of a computerized clinical decision support system on reducing inappropriate antimicrobial use: a randomized controlled trial. J Am Med Inform Assoc. 2006;13(4):378-84.
70. Camins BC, King MD,Wells JB, et al. Impact of an antimicrobial utilization program on antimicrobial use at a large teaching hospital: a randomized controlled trial. Infect Control Hosp Epidemiol. 2009;30(10):931-8. Authors present a randomized controlled trial evaluating active audit and feedback versus passive, indicationbased guidelines alone for the appropriate prescription of broadspectrum antimicrobials among internal medicine teams in a 953-bed teaching hospital. Teams receiving active intervention were significantly more likely to prescribe targeted antimicrobials appropriately compared to controls receiving only passive guidelines. This study exemplifies how passive and active interventions can be combined, and that active interventions produce a larger effect on appropriate prescribing.
71. Solomon DH, Van Houten L, Glynn RJ, et al. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med. 2001;161(15):1897-902.
72. Cosgrove SE, Seo SK, Bolon MK, et al. Evaluation of postprescription review and feedback as a method of promoting rational antimicrobial use: a multicenter intervention. Infect Control Hosp Epidemiol. 2012;33(4):374-80. This is the first multicenter study to evaluate an active AS intervention. The authors performed a quasiexperimental study to determine the effect of prospective audit and feedback on antimicrobial utilization of six targeted antibiotic classes among five academic medical centers. Only two of five centers experienced significant decreases in utilization during the study period, which the authors attribute to these centers having well-established ASPs.
73. Omidvari K, de Boisblanc BP, Karam G, Nelson S, Haponik E, Summer W. Early transition to oral antibiotic therapy for community-Acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Resp Med. 1998;92(8):1032-9.
74. Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ. 2006;333(7580):1193.
75. Policy Statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol. 2012;33(4):322-327.
76. Centers for Medicare and Medicaid Services. Survey and certification focus on patient safety and quality -draft surveyor worksheets. Section 1.C. Systems to prevent transmission of MDROs and promote antibiotic stewardship, surveillance. https://www.cms.gov/Surveycertificationgeninfo/downloads/ SCLetter12-01.pdf. Accessed 25 Aug 2012.
77. Centers for Disease Control and Prevention. National Healthcare Safety Network: Medication-Associated Module. Antimicrobial Use and Resistance (AUR) Option. http://www.cdc.gov/nhsn/psc-ma.html. Accessed 25 Aug 2012.
78. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis. 2007;44(5):664-70.
79. Polk RE, Hohmann SF, Medvedev S, Ibrahim O. Benchmarking risk-Adjusted adult antibacterial drug use in 70 US academic medical center hospitals. Clin Infect Dis. 2011;53(11):1100-10. The authors present the sentinel study of benchmarking and interfacility comparison of antibiotic utilization data. Investigators collected days of therapy (DOT) and length of therapy (LOT) as well as administrative billing data on over 1.7 million patients from 70 US academic centers in the University HealthSystem Consortium. The purpose of the study was to better characterize antimicrobial use nationwide and develop risk-Adjustment and benchmarking methods.